Clinical Trials on Meningococcal Vaccines in Chile

Total 14 results

Novartis Vaccines

Completed

Assessment of Antibody Persistence at Eighteen Months After the Completion of the Vaccination Course in Study V72P10

Meningococcal Disease | Meningococcal Meningitis

Chile
GlaxoSmithKline

Completed

A Study to Evaluate 4-year Antibody Persistence and Booster Response Following MenABCWY Vaccination in Healthy Adolescents and Young Adults Who Previously Participated in Studies V102_02 (NCT01210885) and V102_02E1 (NCT01367158)

Meningococcal Disease | Infections, Meningococcal

Colombia, Panama, Chile
Novartis Vaccines

Completed

Immunogenicity and Safety of Different rMenB Plus MenACWY Formulations in Adolescents

Meningococcal Disease | Meningococcal Meningitis

Chile, Colombia, Panama
Novartis Vaccines

Completed

Safety, Tolerability and Immunogenicity of a Third Dose of One of Four Different Formulations of rMenB + MenACWY Combination Vaccine in Adolescents Who Previously Received the Same Study Vaccines

Meningococcal Disease | Meningococcal Meningitis

Chile, Colombia, Panama
GlaxoSmithKline

Completed

Combined Study - Phase 3b MenB Long Term Persistence in Adolescents

Infections, Meningococcal

Chile, Canada, Australia
Pontificia Universidad Catolica de Chile

Completed

Immune Response to Anti COVID-19 Vaccine in Immunocompromised Patients: a Cohort Study

Covid19 | COVID-19 Vaccines

Chile
Pontificia Universidad Catolica de Chile
Sinovac Biotech Co., Ltd; Ministry of Health, Chile

Active, not recruiting

Efficacy, Safety, and Immunogenicity of Two Vaccination Schedules of an Inactivated Vaccine Against COVID-19 in Adults (CoronaVac3CL)

Covid19 | Vaccines

Chile
Novartis Vaccines

Completed

Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine Administered to Healthy Adolescents According to Different Vaccination Schedules

Meningococcal Disease

Chile
Pontificia Universidad Catolica de Chile
Sinovac Life Sciences Co., Ltd.

Completed

Immunogenicity Evaluation of Omicron Variant-based Vaccine and a Trivalent Vaccine in Adults Against COVID-19 in Chile (CoronaVarCL)

COVID-19 | Vaccines

Chile
Pontificia Universidad Catolica de Chile
Sinovac Biotech Co., Ltd; Sinovac Biotech (Chile) SpA

Recruiting

Phase Ⅲ, Clinical Trial to Compare an Inactivated Quadrivalent Influenza Vaccine and a Licensed Vaccine in Chile (TetraFluVac)

Influenza | Vaccines

Chile
Pontificia Universidad Catolica de Chile

Completed

Immune Response to Third Dose of COVID-19 Vaccine in Solid Organ Transplant

COVID-19 | SARS-CoV-2 Infection | Solid Organ Transplant | Vaccine Response Impaired

Chile
Novartis Vaccines

Completed

Safety and Immunogenicity in Dose-Ranging and Formulation-Finding Meningococcal B (MenB) Vaccine Study in 2-month-old Infants

Meningococcal Infections | Meningococcal Meningitis

Argentina, Chile, Czech Republic, Hungary, Italy
Pfizer

Completed

A Global Phase 3 Safety Study of 120 mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years

Meningitis, Meningococcal

United States, Australia, Spain, Chile, Finland, Denmark, Estonia, Czech Republic, Germany, Lithuania, Poland, Sweden
Sanofi Pasteur, a Sanofi Company

Completed

Study of the Safety of Menactra® Vaccine When Administered With Other Pediatric Vaccines to Healthy Toddlers

Measles | Rubella | Mumps | Varicella | Meningococcal Meningitis

United States, Chile

3

Subscribe